Trenchant BioSystems and Invetech agreed to collaborate on the continued development of Trenchant’s fully automated AutoCell Platform, intended for future commercialization.
According to company officials, testing data previously announced in January demonstrate that Trenchant’s AutoCell platform has shown the potential to support manufacturing workflows that could reduce or eliminate certain ex vivo expansion steps. Essentially, Trenchant says, the data supports that Trenchant’s fully automated CGT manufacturing solution could significantly reduce cell and gene therapy manufacturing costs as well as manufacturing time.
In addition, the data showed that T-cells could be sourced from a single unit of whole blood drawn from the patient. The completion of the final stages of development of the AutoCell product will aim to implement full automation of the end-to-end CGT manufacturing process at the point of care.
Invetech is expected to provide engineering, development, and manufacturing support services. To achieve this, Invetech will utilize its experience in cell and gene therapy, including in-house development and manufacturing. This includes an over 20-year track record of working with tool providers and therapy manufacturers, from early-stage companies and CDMOs to big pharma organizations.
Trenchant currently plans a first phase launch of an early access platform for select partners in early 2027, with full commercial release later in 2027.
“Current cell and gene therapy manufacturing practices are too time consuming and costly to be scalable to serve large-scale patient populations,” states Jon Ellis, CEO, Trenchant. “[We have] now released internal and independent data that confirms that the AutoCell product holds the solution to these challenges.”
“Trenchant’s AutoCell has the potential to realize the dream of distributed (Point-of-Care) manufacturing, with the additional benefits of significantly reduced COGs, thus enabling accessibility and affordability of treatment for essentially every patient in treatment centers anywhere around the world,” added Andreas Knaack, CEO, Invetech.
The post Fully-Automated CGT Manufacturing Platform Jointly Being Targeted by Trenchant BioSystems and Invetech appeared first on GEN – Genetic Engineering and Biotechnology News.
